[go: up one dir, main page]

WO1999000130A1 - Methode de traitement de la vestibulite vulvaire - Google Patents

Methode de traitement de la vestibulite vulvaire Download PDF

Info

Publication number
WO1999000130A1
WO1999000130A1 PCT/US1998/013193 US9813193W WO9900130A1 WO 1999000130 A1 WO1999000130 A1 WO 1999000130A1 US 9813193 W US9813193 W US 9813193W WO 9900130 A1 WO9900130 A1 WO 9900130A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition comprises
composition
sodium
patients
vulvar vestibulitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/013193
Other languages
English (en)
Inventor
Paul Nyirjesy
Steven P. Gelone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Priority to AU81673/98A priority Critical patent/AU8167398A/en
Priority to US09/219,975 priority patent/US6150400A/en
Publication of WO1999000130A1 publication Critical patent/WO1999000130A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • This invention relates to methods and compositions for the treatment of vulvar vestibulitis.
  • Vulvodynia is a complex gynecologic syndrome characterized by unexplained vulvar pain, sexual dysfunction, and psychological disability. It is one of the most perplexing problems faced by the practicing gynecologist. Although the exact prevalence of vulvodynia is unknown, the condition is relatively common. In a vaginitis referral population symptoms are present in as many as 15-20% of the patients seen. It has been estimated that V ⁇ million American women may suffer from some degree of vulvodynia. Vulvodynia can have multiple etiologies, and several subtypes have been recognized.
  • Vulvar vestibulitis may become chronic if the cause becomes persistent or recurrent. Chronic vulvar vestibulitis may also persist long after all suspected causes have been treated. And many cases of chronic vulvar vestibulitis are of unknown etiology. Although no direct cause and effect relationship has been shown, it has been suggested that oxalates in the urine, altered vaginal pH, localized peripheral neuropathy, and subclinical viral infections can all contribute to the syndrome.
  • the first-line therapy for vulvar vestibulitis is the treatment of its suspected causes. This includes the pharmacologic treatment of infections and the discontinued use of the irritants and therapeutic agents, local and systemic, that may contribute to the problem. Topical anesthetics, corticosteroids, and sex hormones may provide some symptomatic relief.
  • treatment of the suspected causes does not lead to a cure.
  • Further treatments may include dietary modifications, physical therapy and biofeedback, the use of topical, oral, or injected therapeutic agents, or surgery.
  • no single treatment works in all patients.
  • many of these approaches involve complex medical procedures, significant costs, and/or undesirable side effects.
  • Oral therapeutic agents which have been used in the treatment of vulvar vestibulitis include isotretinoin, dapsone, acyclovir, and tricyclic anti- depressants such as amitriptyline.
  • Isotretinoin can cause mucocutaneous, gastrointestinal, cerebral, ocular and metabolic side effects, as well as severe fetal malformation in the event of pregnancy.
  • Dapsone can cause anemia, jaundice, gastrointestinal distress, and weakness, and requires the monitoring of hemoglobin, hematocrit, and white cell count.
  • Acyclovir can cause headaches and mild gastrointestinal upset.
  • the side effects of the tricyclic antidepressants include drowsiness, weight gain, and dry mouth.
  • Cromolyn sodium has been used to manage the symptoms of allergic vaginitis generally and seminal fluid hypersensitivity specifically. It has also been used in patients with vulvar intraepithelial neoplasia.
  • Vestibule or "vulvar vestibule” is the space behind the glans clitoridis and between the labia minora, containing the openings of the vagina and urethra, and ducts of the vestibular glands.
  • the first prospective double-blind, placebo-controlled study of a therapy for vulvar vestibulitis is designed to test the efficacy of cromolyn sodium in the treatment of vulvar vestibulitis, and also to test whether symptoms recur after discontinuation of therapy.
  • cromolyn sodium provides a clinical benefit in the treatment of vulvar vestibulitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode améliorée permettant de traiter la vestibulité vulvaire chez une patiente. Le procédé consiste à appliquer sur le vestibule vulvaire de la patiente une quantité efficace d'une composition comprenant un composé qui inhibe la libération de médiateurs par les mastocytes. Cette méthode est simple, peu coûteuse, bien tolérée et efficace dans la plupart des cas.
PCT/US1998/013193 1997-06-30 1998-06-25 Methode de traitement de la vestibulite vulvaire Ceased WO1999000130A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU81673/98A AU8167398A (en) 1997-06-30 1998-06-25 Method for treating vulvar vestibulitis
US09/219,975 US6150400A (en) 1997-06-30 1998-12-23 Method for treating vulvar vestibulitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5126497P 1997-06-30 1997-06-30
US60/051,264 1997-06-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/219,975 Continuation-In-Part US6150400A (en) 1997-06-30 1998-12-23 Method for treating vulvar vestibulitis

Publications (1)

Publication Number Publication Date
WO1999000130A1 true WO1999000130A1 (fr) 1999-01-07

Family

ID=21970251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013193 Ceased WO1999000130A1 (fr) 1997-06-30 1998-06-25 Methode de traitement de la vestibulite vulvaire

Country Status (2)

Country Link
AU (1) AU8167398A (fr)
WO (1) WO1999000130A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225356B1 (en) * 2000-01-20 2001-05-01 Jones, Iii Tudor Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea
US7582652B2 (en) 2004-01-30 2009-09-01 Eli Lilly And Company Kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAIM W, ET AL.: "VULVAR VESTIBULITIS SUBJECTS UNDERGOING SURGICAL INTERVENTION: A DESCRIPTIVE ANALYSIS AND HISTOPHATHOLOGICAL CORRELATES", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, ELSEVIER IRELAND LTD., IE, vol. 68, 1 January 1996 (1996-01-01), IE, pages 165 - 168, XP002913305, ISSN: 0301-2115, DOI: 10.1016/0301-2115(96)02502-X *
MARINOFF S C, TURNER M L C: "VULVAR VESTIBULITIS SYNDROME: AN OVERVIEW", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 165, no. 04, 1 October 1991 (1991-10-01), US, pages 1228 - 1233, XP002913304, ISSN: 0002-9378 *
OLIN B R, ET AL.: "RESPIRATORY INHALENT PRODUCTS", DRUG FACTS AND COMPARISONS, XX, XX, 1 January 1987 (1987-01-01), XX, pages 182G - 182H + 825, XP002913303 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225356B1 (en) * 2000-01-20 2001-05-01 Jones, Iii Tudor Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea
US7582652B2 (en) 2004-01-30 2009-09-01 Eli Lilly And Company Kinase inhibitors

Also Published As

Publication number Publication date
AU8167398A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
US6150400A (en) Method for treating vulvar vestibulitis
Rein et al. Trichomoniasis, candidiasis, and the minor venereal diseases
Hellberg et al. Self-treatment of female external genital warts with 0.5% Podophyllotoxin cream (Condyline®) vs weekly applications of 20% Podophyllin Solution
McKay Vulvitis and vulvovaginitis: cutaneous considerations
Brown et al. Clinical and virologic course of herpes simplex genitalis
Mauck et al. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II
JP7344911B2 (ja) 頸部障害の処置のためのロピナビルおよびリトナビル
Syed et al. Management of genital warts in women with human leukocyte interferon-α vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study
US20090197946A1 (en) Composition and method for treatment of inflamation and infections of the genitalia, contraceptive and the prophylaxis of sexually transmitted diseases
WO1999000130A1 (fr) Methode de traitement de la vestibulite vulvaire
Tummon et al. Genital herpes simplex
Regidor et al. Treatment and prevention of trichomoniasis, bacterial vaginosis and candidiasis with a new 7-day regime containing metronidazole and miconazole in a single vaginal pessary
EP3498276B1 (fr) Ectoïne et de dérivés d'ectoïne à utiliser dans des maladies vulvo-vaginales
Fischer Treatment of vaginitis and vulvitis
RU2601913C2 (ru) Трансвагинальные ингибиторы фосфодиэстеразы для лечения бесплодия
Kim Treatment and management of sexually transmitted diseases
US7687078B1 (en) Method of treatment
AL-Khikani Refractory Fungal Vaginitis Treated By Topical Amphotericin B. Review
RU2262948C1 (ru) Способ лечения кандидозного вульвовагинита у беременных
Enterline et al. Condylomata acuminata (venereal warts)
Patel et al. A Female Patient with Vulvar Pruritus
SCHNEIDER et al. Vaginitis in adolescent girls
CN119013028A (zh) 改善性敏感障碍的组合物和方法
Boardman et al. Managing Vulvar Infections: HPV Related Disease and Candidiasis
Clow A new agent for the treatment of vaginal candidiasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505709

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA